Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Clearmind Medicine Inc. - Common Shares (NQ:CMND)

1.640 -0.110 (-6.29%)

Streaming Delayed Price Updated: 2:15 PM EDT, Aug 7, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	67,029
Open	1.740
Bid (Size)	1.640 (300)
Ask (Size)	1.690 (200)
Prev. Close	1.750
Today's Range	1.580 - 1.760
52wk Range	1.430 - 524.00
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study

August 06, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

What's going on in today's pre-market session ↗

August 03, 2026

Via Chartmill

Performance

YTD	-91.8%	-91.8%
1 Month	-22.6%	-22.6%
3 Month	-70.8%	-70.8%
6 Month	-88.7%	-88.7%
1 Year	-99.6%	-99.6%

More News

Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company

August 03, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial

July 30, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial

July 28, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market

July 20, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction

July 17, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI

July 16, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial

July 13, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative

July 10, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI

July 07, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength

June 29, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial

June 22, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators

June 18, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial

June 16, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Monday's pre-market session: top gainers and losers ↗

June 08, 2026

Via Chartmill

There are notable gap-ups and gap-downs in today's session. ↗

June 05, 2026

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

June 05, 2026

Via Chartmill

Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar

June 05, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Stocks to Watch: ANY, CMND, PRFX, OLOX, IGC Data Centers, AI, Quantum & Healthcare

June 03, 2026

Via AB Newswire

Monday's session: gap up and gap down stocks ↗

June 01, 2026

Via Chartmill

Top stock movements in today's session. ↗

May 29, 2026

Via Chartmill

Friday's session: gap up and gap down stocks ↗

May 29, 2026

Via Chartmill

Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment

May 29, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts

May 26, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Clearmind Medicine Inc. - Common Shares publicly traded?

Yes, Clearmind Medicine Inc. - Common Shares is publicly traded.

What exchange does Clearmind Medicine Inc. - Common Shares trade on?

Clearmind Medicine Inc. - Common Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Clearmind Medicine Inc. - Common Shares?

The ticker symbol for Clearmind Medicine Inc. - Common Shares is CMND on the Nasdaq Stock Market

What is the current price of Clearmind Medicine Inc. - Common Shares?

The current price of Clearmind Medicine Inc. - Common Shares is 1.640

When was Clearmind Medicine Inc. - Common Shares last traded?

The last trade of Clearmind Medicine Inc. - Common Shares was at 08/07/26 02:15 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.